Gene therapy for metachromatic leukodystrophy

Jonathan B. Rosenberg, Stephen M. Kaminsky, Patrick Aubourg, Ronald Crystal, Dolan Sondhi

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Leukodystrophies (LDs) are rare, often devastating genetic disorders with neurologic symptoms. There are currently no disease-specific therapeutic approaches for these diseases. In this review we use metachromatic leukodystrophy as an example to outline in the brief the therapeutic approaches to MLD that have been tested in animal models and in clinical trials, such as enzyme-replacement therapy, bone marrow/umbilical cord blood transplants, ex vivo transplantation of genetically modified hematopoietic stem cells, and gene therapy. These studies suggest that to be successful the ideal therapy for MLD must provide persistent and high level expression of the deficient gene, arylsulfatase A in the CNS. Gene therapy using adeno-associated viruses is therefore the ideal choice for clinical development as it provides the best balance of potential for efficacy with reduced safety risk. Here we have summarized the published preclinical data from our group and from others that support the use of a gene therapy with AAVrh.10 serotype for clinical development as a treatment for MLD, and as an example of the potential of gene therapy for LDs especially for Krabbe disease, which is the focus of this special issue.

Original languageEnglish
Pages (from-to)1169-1179
Number of pages11
JournalJournal of Neuroscience Research
Volume94
Issue number11
DOIs
Publication statusPublished - 1 Nov 2016
Externally publishedYes

Fingerprint

Metachromatic Leukodystrophy
Genetic Therapy
Globoid Cell Leukodystrophy
Cerebroside-Sulfatase
Enzyme Replacement Therapy
Dependovirus
Inborn Genetic Diseases
Therapeutics
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Neurologic Manifestations
Fetal Blood
Animal Models
Transplantation
Bone Marrow
Clinical Trials
Transplants
Safety
Gene Expression

Keywords

  • adeno-associated virus
  • clinical development
  • clinical translation
  • gene therapy
  • metachromatic leukodystrophy

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

Rosenberg, J. B., Kaminsky, S. M., Aubourg, P., Crystal, R., & Sondhi, D. (2016). Gene therapy for metachromatic leukodystrophy. Journal of Neuroscience Research, 94(11), 1169-1179. https://doi.org/10.1002/jnr.23792

Gene therapy for metachromatic leukodystrophy. / Rosenberg, Jonathan B.; Kaminsky, Stephen M.; Aubourg, Patrick; Crystal, Ronald; Sondhi, Dolan.

In: Journal of Neuroscience Research, Vol. 94, No. 11, 01.11.2016, p. 1169-1179.

Research output: Contribution to journalReview article

Rosenberg, JB, Kaminsky, SM, Aubourg, P, Crystal, R & Sondhi, D 2016, 'Gene therapy for metachromatic leukodystrophy', Journal of Neuroscience Research, vol. 94, no. 11, pp. 1169-1179. https://doi.org/10.1002/jnr.23792
Rosenberg JB, Kaminsky SM, Aubourg P, Crystal R, Sondhi D. Gene therapy for metachromatic leukodystrophy. Journal of Neuroscience Research. 2016 Nov 1;94(11):1169-1179. https://doi.org/10.1002/jnr.23792
Rosenberg, Jonathan B. ; Kaminsky, Stephen M. ; Aubourg, Patrick ; Crystal, Ronald ; Sondhi, Dolan. / Gene therapy for metachromatic leukodystrophy. In: Journal of Neuroscience Research. 2016 ; Vol. 94, No. 11. pp. 1169-1179.
@article{be63cab4997d452ab520170b710a6c82,
title = "Gene therapy for metachromatic leukodystrophy",
abstract = "Leukodystrophies (LDs) are rare, often devastating genetic disorders with neurologic symptoms. There are currently no disease-specific therapeutic approaches for these diseases. In this review we use metachromatic leukodystrophy as an example to outline in the brief the therapeutic approaches to MLD that have been tested in animal models and in clinical trials, such as enzyme-replacement therapy, bone marrow/umbilical cord blood transplants, ex vivo transplantation of genetically modified hematopoietic stem cells, and gene therapy. These studies suggest that to be successful the ideal therapy for MLD must provide persistent and high level expression of the deficient gene, arylsulfatase A in the CNS. Gene therapy using adeno-associated viruses is therefore the ideal choice for clinical development as it provides the best balance of potential for efficacy with reduced safety risk. Here we have summarized the published preclinical data from our group and from others that support the use of a gene therapy with AAVrh.10 serotype for clinical development as a treatment for MLD, and as an example of the potential of gene therapy for LDs especially for Krabbe disease, which is the focus of this special issue.",
keywords = "adeno-associated virus, clinical development, clinical translation, gene therapy, metachromatic leukodystrophy",
author = "Rosenberg, {Jonathan B.} and Kaminsky, {Stephen M.} and Patrick Aubourg and Ronald Crystal and Dolan Sondhi",
year = "2016",
month = "11",
day = "1",
doi = "10.1002/jnr.23792",
language = "English",
volume = "94",
pages = "1169--1179",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "11",

}

TY - JOUR

T1 - Gene therapy for metachromatic leukodystrophy

AU - Rosenberg, Jonathan B.

AU - Kaminsky, Stephen M.

AU - Aubourg, Patrick

AU - Crystal, Ronald

AU - Sondhi, Dolan

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Leukodystrophies (LDs) are rare, often devastating genetic disorders with neurologic symptoms. There are currently no disease-specific therapeutic approaches for these diseases. In this review we use metachromatic leukodystrophy as an example to outline in the brief the therapeutic approaches to MLD that have been tested in animal models and in clinical trials, such as enzyme-replacement therapy, bone marrow/umbilical cord blood transplants, ex vivo transplantation of genetically modified hematopoietic stem cells, and gene therapy. These studies suggest that to be successful the ideal therapy for MLD must provide persistent and high level expression of the deficient gene, arylsulfatase A in the CNS. Gene therapy using adeno-associated viruses is therefore the ideal choice for clinical development as it provides the best balance of potential for efficacy with reduced safety risk. Here we have summarized the published preclinical data from our group and from others that support the use of a gene therapy with AAVrh.10 serotype for clinical development as a treatment for MLD, and as an example of the potential of gene therapy for LDs especially for Krabbe disease, which is the focus of this special issue.

AB - Leukodystrophies (LDs) are rare, often devastating genetic disorders with neurologic symptoms. There are currently no disease-specific therapeutic approaches for these diseases. In this review we use metachromatic leukodystrophy as an example to outline in the brief the therapeutic approaches to MLD that have been tested in animal models and in clinical trials, such as enzyme-replacement therapy, bone marrow/umbilical cord blood transplants, ex vivo transplantation of genetically modified hematopoietic stem cells, and gene therapy. These studies suggest that to be successful the ideal therapy for MLD must provide persistent and high level expression of the deficient gene, arylsulfatase A in the CNS. Gene therapy using adeno-associated viruses is therefore the ideal choice for clinical development as it provides the best balance of potential for efficacy with reduced safety risk. Here we have summarized the published preclinical data from our group and from others that support the use of a gene therapy with AAVrh.10 serotype for clinical development as a treatment for MLD, and as an example of the potential of gene therapy for LDs especially for Krabbe disease, which is the focus of this special issue.

KW - adeno-associated virus

KW - clinical development

KW - clinical translation

KW - gene therapy

KW - metachromatic leukodystrophy

UR - http://www.scopus.com/inward/record.url?scp=84990241082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990241082&partnerID=8YFLogxK

U2 - 10.1002/jnr.23792

DO - 10.1002/jnr.23792

M3 - Review article

VL - 94

SP - 1169

EP - 1179

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 11

ER -